Lakefront Biotherapeutics (LKFT) Capital Leases (2014 - 2017)

Lakefront Biotherapeutics (LKFT) has 4 years of Capital Leases data on file, last reported at $10596.9 in Q4 2017.

• Capital Leases for Q4 2017 came in at $10596.9, up 9.05% year-over-year; the trailing twelve-month figure through Dec 2017 was $10596.9 (up 9.05% YoY), and the FY2017 annual result was $10596.9, up 9.05% from the prior year.
• Capital Leases retreated to $10596.9 in Q4 2017 per LKFT's latest filing, from $40683.3 in the prior quarter.
• Over five years, Capital Leases peaked at $143730.9 in Q4 2014 and troughed at $9717.5 in Q4 2016.
• A 4-year average of $52694.2 and a median of $41805.4 in 2016 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2016 and 2017: Capital Leases tumbled 85.93% in 2016, then grew 9.05% in 2017.
• A 4-year view of Capital Leases shows it stood at $143730.9 in 2014, then plunged by 51.96% to $69055.4 in 2015, then plunged by 85.93% to $9717.5 in 2016, then rose by 9.05% to $10596.9 in 2017.
• Business Quant data shows LKFT's Capital Leases at $10596.9 in Q4 2017, $40683.3 in Q2 2017, and $53270.3 in Q1 2017.